SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-025617
Filing Date
2024-02-20
Accepted
2024-02-20 17:23:07
Documents
17
Period of Report
2024-02-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm246746d1_8k.htm   iXBRL 8-K 30844
2 EXHIBIT 1.1 tm246746d1_ex1-1.htm EX-1.1 343496
3 EXHIBIT 99.1 tm246746d1_ex99-1.htm EX-99.1 10982
7 GRAPHIC tm246746d1_ex99-1img001.jpg GRAPHIC 6914
  Complete submission text file 0001104659-24-025617.txt   654530

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA iova-20240220.xsd EX-101.SCH 3003
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20240220_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20240220_pre.xml EX-101.PRE 22351
18 EXTRACTED XBRL INSTANCE DOCUMENT tm246746d1_8k_htm.xml XML 3633
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

IRS No.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 24655020
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)